Skip to contentA
Adma Biologics, Inc.
A
ADMAAdma Biologics, Inc. Released Mar 6, 2013, after the close
10-K filed Mar 6, 2013, 65 days after period end · 0001193805-13-000585
Q4 2012 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$523.28K$523.28Kderivedno prior Q4 2011 on file+45.2% vs Q3 2012 No earnings release is on file for this quarter. Its figures came with the 10-K.
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Adma Biologics, Inc. · CIK 1368514 · Engraved from SEC EDGAR
Net Income-$2.25M-$2.25MderivedN/M vs Q4 2011N/M vs Q3 2012 EPS, diluted—Not derived. Share counts vary by quarter.
Gross Profitderived$142,989— Operating Incomederived-$2,240,307N/M Operating Cash Flowderived-$1,807,050N/M Free Cash Flowderived-$1,842,382N/M Margins · derivedGross margin27.3%
Operating margin-428.1%
Net margin-430.3%
ended Dec 31, 2012 · filed Mar 6, 2013 · 65 d after period end